Based on its recent analysis of the global artificial intelligence (AI)-enabled drug discovery industry, Frost & Sullivan recognizes Insilico Medicine with the 2022 Entrepreneurial Company...
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma”; Stock Code: 600196.SH, 02196.HK), a leading innovation-driven international healthcare group in China and Insilico Medicine (“Insilico”), an end-to-end...
Huadong Medicine (SZ.000963) and Insilico Medicine (“Insilico”), an end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that the companies have entered into a co-development...
Insilico Medicine (“Insilico”), an end-to-end artificial intelligence-driven drug discovery company, and BioNova Pharmaceuticals (Shanghai) Ltd. (“BioNova”), a clinical-stage biopharmaceutical company, today announced entry into a collaboration...
Insilico Medicine and ChemDiv, Inc. launched a new strategic collaboration to provide certain pharmaceutical and biotechnology companies with end-to-end drug discovery solutions. This collaboration combines...